Cargando…

Gut Microbiota Modulation as a Potential Target for the Treatment of Lung Infections

The gastrointestinal and respiratory systems are colonized by a complex ecosystem of microorganisms called the microbiota. These microorganisms co-evolved over millions of years with the host, creating a symbiotic relationship that is fundamental for promoting host homeostasis by producing bioactive...

Descripción completa

Detalles Bibliográficos
Autores principales: Cruz, Clênio Silva, Ricci, Mayra Fernanda, Vieira, Angélica Thomaz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453009/
https://www.ncbi.nlm.nih.gov/pubmed/34557097
http://dx.doi.org/10.3389/fphar.2021.724033
_version_ 1784570202973798400
author Cruz, Clênio Silva
Ricci, Mayra Fernanda
Vieira, Angélica Thomaz
author_facet Cruz, Clênio Silva
Ricci, Mayra Fernanda
Vieira, Angélica Thomaz
author_sort Cruz, Clênio Silva
collection PubMed
description The gastrointestinal and respiratory systems are colonized by a complex ecosystem of microorganisms called the microbiota. These microorganisms co-evolved over millions of years with the host, creating a symbiotic relationship that is fundamental for promoting host homeostasis by producing bioactive metabolites and antimicrobial molecules, and regulating the immune and inflammatory responses. Imbalance in the abundance, diversity, and function of the gut microbiota (known as dysbiosis) have been shown to increase host susceptibility to infections in the lungs, suggesting crosstalk between these organs. This crosstalk is now referred to as the gut-lung axis. Hence, the use of probiotics, prebiotics, and synbiotics for modulation of gut microbiota has been studied based on their effectiveness in reducing the duration and severity of respiratory tract infections, mainly owing to their effects on preventing pathogen colonization and modulating the immune system. This review discusses the role and responses of probiotics, prebiotics, and synbiotics in the gut-lung axis in the face of lung infections.
format Online
Article
Text
id pubmed-8453009
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-84530092021-09-22 Gut Microbiota Modulation as a Potential Target for the Treatment of Lung Infections Cruz, Clênio Silva Ricci, Mayra Fernanda Vieira, Angélica Thomaz Front Pharmacol Pharmacology The gastrointestinal and respiratory systems are colonized by a complex ecosystem of microorganisms called the microbiota. These microorganisms co-evolved over millions of years with the host, creating a symbiotic relationship that is fundamental for promoting host homeostasis by producing bioactive metabolites and antimicrobial molecules, and regulating the immune and inflammatory responses. Imbalance in the abundance, diversity, and function of the gut microbiota (known as dysbiosis) have been shown to increase host susceptibility to infections in the lungs, suggesting crosstalk between these organs. This crosstalk is now referred to as the gut-lung axis. Hence, the use of probiotics, prebiotics, and synbiotics for modulation of gut microbiota has been studied based on their effectiveness in reducing the duration and severity of respiratory tract infections, mainly owing to their effects on preventing pathogen colonization and modulating the immune system. This review discusses the role and responses of probiotics, prebiotics, and synbiotics in the gut-lung axis in the face of lung infections. Frontiers Media S.A. 2021-09-07 /pmc/articles/PMC8453009/ /pubmed/34557097 http://dx.doi.org/10.3389/fphar.2021.724033 Text en Copyright © 2021 Cruz, Ricci and Vieira. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Cruz, Clênio Silva
Ricci, Mayra Fernanda
Vieira, Angélica Thomaz
Gut Microbiota Modulation as a Potential Target for the Treatment of Lung Infections
title Gut Microbiota Modulation as a Potential Target for the Treatment of Lung Infections
title_full Gut Microbiota Modulation as a Potential Target for the Treatment of Lung Infections
title_fullStr Gut Microbiota Modulation as a Potential Target for the Treatment of Lung Infections
title_full_unstemmed Gut Microbiota Modulation as a Potential Target for the Treatment of Lung Infections
title_short Gut Microbiota Modulation as a Potential Target for the Treatment of Lung Infections
title_sort gut microbiota modulation as a potential target for the treatment of lung infections
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453009/
https://www.ncbi.nlm.nih.gov/pubmed/34557097
http://dx.doi.org/10.3389/fphar.2021.724033
work_keys_str_mv AT cruzcleniosilva gutmicrobiotamodulationasapotentialtargetforthetreatmentoflunginfections
AT riccimayrafernanda gutmicrobiotamodulationasapotentialtargetforthetreatmentoflunginfections
AT vieiraangelicathomaz gutmicrobiotamodulationasapotentialtargetforthetreatmentoflunginfections